Baird Financial Group
PDLI

Baird Financial Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Baird Financial Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-59,103
Closed -$297K – 1330
2015
Q3 		$297K Sell
59,103
-9,160
-13% -$52.5K ﹤0.01% 1058
2015
Q2 		$439K Buy
+68,263
New +$457K ﹤0.01% 1006

Other funds holding PDLI

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Baird Financial Group's PDLI Position: Q4 2015 in Review

Baird Financial Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2015, closing a stake of 59,103 shares — an estimated $297K sold.

Baird Financial Group first reported a position in PDLI in Q2 2015 and held it in 2 quarters. The position peaked at $439K in Q2 2015. 204 funds tracked by Wall St. Rank hold PDLI as of Q4 2015.

  • Baird Financial Group reported no remaining PDL BioPharma, Inc. position as of Q4 2015 after selling out during the quarter.
  • Baird Financial Group sold 59,103 PDL BioPharma, Inc. shares in Q4 2015, an estimated $297K.
  • Baird Financial Group first reported a position in PDL BioPharma, Inc. in Q2 2015 and held it in 2 quarters.
  • Baird Financial Group's PDL BioPharma, Inc. position peaked at $439K in Q2 2015.
  • 204 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2015.

Based on Baird Financial Group's 13F filing for Q4 2015, filed 11 Feb 2016.